Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals, Inc.
  • About Us
  • Our Science
  • Pipeline
  • Development Programs
  • Investors & Collaborators
  • News
  • Medical Information
    • Publications
    • Expanded Access
  • Contact
  • Privacy Policy
  • Disclaimer
✕

Medical Information

  • Publications
  • Expanded Access

© 2017 - 2025 Nacuity Pharmaceuticals, Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
✕
conner_200

Halden Conner

Chairman, CEO, Co-Founder

  • Former Alcon Laboratories Board Member
  • Former Wilmer Advisory Council Member
  • Co-founder, Protom International
✕
mwall_2

G. Michael Wall, Ph.D.

SVP, CSO

  • 22 years at Alcon Laboratories, directing all phases of ophthalmic, otic, nasal drug development, numerous products
  • >40 patents, >100 pubs, 2 books, 3 chapters,
  • Directed more than 40 clinical trials
  • PhD, Med Chem, University of Mississippi School of Pharmacy
  • Harvard Business School AMP
✕
kern

Jami R. Kern, MBA, Ph.D.

SVP, CCO

  • Extensive experience, pharmaceutical and medical device industries
  • Led clinical development and medical affairs at Alcon Research for 15 years
  • MBA, Neeley School of Business at TCU, Ph.D. in Biomedical Science, Molecular Bio & Biochem, UNT Health Science Center
✕
anderson_200

Lee Anderson, M.D.

Ophthalmologist in Residence

  • Over 20 years in practice specializing in Ophthalmology and Retinal Disease
  • M.D., University of Texas Medical Branch
  • Fellowship Bascom Palmer Eye Institute
✕
lieser_200

Charles Lieser, J.D., CPA

CFO

  • Owner, Weaver, LLP, 32 years
  • 40 plus years experience public accounting
  • Principal and advisor to numerous companies
✕
cagle_200

Gerald D. Cagle, Ph.D.

  • Former Global Head R&D, Chief Scientific Officer, & VP Regulatory Affairs, Alcon Laboratories
  • >20 issued patents and numerous peer reviewed scientific articles
  • Director, Aerie, Clearside Biomedical, GrayBug Drug Delivery and FFB-CRI
✕
Emmett-Cunningham-Headshot200x200

Emmett T. Cunningham, Jr.
M.D., Ph.D., MPH

  • Senior Partner, HealthQuest Capital Management
  • Co-Founder and Executive Chairman, Eyconis, Inc.
  • Former Senior Managing Director, Blackstone, Inc.
  • Co-Founder and former Chairman, Ophthalmology Innovation Summit (OIS)
✕
russell_kelley-05_crop_bod

Russell Kelley, Ph.D., M.B.A.

  • Managing Director, RD Fund
  • Former Scientist, Director and Head of preclinical, Tengion
  • Board Director, Opus Genetics and SparingVision
  • Board Observer, Atsena Therapeutics, Perceive Bio, Amber Bio and Perceive Pharma
✕
steele_200

Robin Steele, J.D., LLM

  • Director, Daré Bioscience, Inc., Coagulant Therapeutics, Inc. and Alveo Technologies, Inc.
  • Former Senior Vice President, General Counsel, and Secretary of InterMune, Inc.
  • Former Vice President of Legal Affairs for North America, Elan Pharmaceuticals, Inc.
✕
wohlberg_200

David Wohlberg, Esq.

  • Vice-Chairman, Co-Founder, Nacuity Pharmaceuticals, Inc.
  • Former President, ImmunoCellular Therapeutics, Inc.
  • Of Counsel, TroyGould PC
✕
yerxa_200

Benjamin R. Yerxa, Ph.D.

  • President, Opus Genetics
  • Former CEO, FFB and RD Fund
  • Former President and Chief Scientific Officer, Envisia Therapeutics
  • Former Chief Scientific Officer, Liquidia Technologies
  • Former Vice President for Research and Development, Clearside Biomedical
✕
birch_200

David Birch, Ph.D.

  • Scientific Director, Retina Foundation of the Southwest
  • Director, Rose-Silverthorne Retinal Degenerations Laboratory
  • Ph.D., University of California, Santa Barbara
✕
holekamp

Nancy Holekamp, M.D.

  • Professor of Clinical Ophthalmology and Visual Sciences, Washington University School of Medicine
  • Director of Retina Services, Pepose Vision Institute
  • M.D., Johns Hopkins University School of Medicine
✕
Richard Lindstrom picture

Richard L. Lindstrom, M.D.

  • Founder and Attending surgeon, Minnesota Eye Consultants
  • Senior Lecturer and Trustee, University Foundation at the University of Minnesota
  • Executive Committee and Board of Directors, American Society of Cataract and Refractive Surgery
  • M.D., University of Minnesota
✕
pennesi_200

Mark Pennesi, M.D., Ph.D.

  • Professor and Chief of Ophthalmic Genetics, Casey Eye Institute
  • Prevent Blindness and FFB development awards for transitional research in RP
  • M.D./Ph.D., Baylor College of Medicine
✕
stout_200

Tim Stout, M.D., Ph.D., MBA

  • Director, Cullen Eye Institute, Baylor College of Medicine
  • Chair, Department of Ophthalmology, Baylor College of Medicine
  • M.D./Ph.D., Baylor College of Medicine
  • MBA University of Oregon
✕
dorfman_200

Scott Dorfman

  • Co-Founder, CEO and Chairman, Odylia Therapeutics
  • Founder, former Chairman and CEO of Innotrac Corporation
  • Board Member: Dropoff, DriverReach, Complemar, Fulcrum Equity Partners, BioNeex, Usher 2020 Foundation
  • BBA, University of Georgia
✕
feller_200

Daniel Feller

  • Owner and CEO, Talisman Healthcare
  • COO, GEM42S Ltd.
  • Board Member: Genetic Cures Australia
  • B.A. (Hons.) in French with International Relations, University of Warwick